A Phase III Study of Accelerated versus Standard Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Germ Cell Tumors

Full Title

Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (AGCT1532) (CIRB)

Purpose

The standard treatment for poor-risk and intermediate-risk germ cell tumors (GCTs), such as testicular cancer, is chemotherapy with the drugs bleomycin, etoposide, and cisplatin (abbreviated BEP) given every three weeks. In this study, researchers want to see if giving BEP chemotherapy every two weeks is more effective for controlling tumor growth than the standard regimen in patients with metastatic intermediate-risk and poor-risk GCTs.

Patients will be randomly assigned to receive one regimen of therapy or the other. BEP is given intravenously (by vein).

Contact

For more information about this study and to inquire about eligibility, please contact Dr. Darren R. Feldman at 646-888-4740.